Asset Details
Do you wish to reserve the book?
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Do you wish to request the book?
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
2019
Overview
Abstract
Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.
Publisher
Endocrine Society,Copyright Oxford University Press,Oxford University Press
Subject
/ Atherosclerosis - prevention & control
/ Complications and side effects
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Humans
/ Hypoglycemic Agents - pharmacology
/ Hypoglycemic Agents - therapeutic use
/ Insulin
/ Reviews
/ Thiazolidinediones - pharmacology
